Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 18/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 17/20 | 0.42 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.38 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6053886 | 0.86 | NT5E (0.42) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC4 | |
| SCHEMBL5662655 | 0.86 | NT5E (0.42) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC4 | |
| SCHEMBL6053674 | 0.86 | NT5E (0.42) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC4 | |
| SCHEMBL5662631 | 0.86 | NT5E (0.42) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC4 | |
| SCHEMBL13328618 | 0.85 | HSP90AB1 (0.44) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC4 | |
| SCHEMBL13328630 | 0.83 | CYP3A4 (0.48) | — | |
| SCHEMBL2913721 | 0.80 | HSP90AB1 (0.42) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC4 | |
| SCHEMBL13714914 | 0.80 | HSP90AB1 (0.43) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC4 | |
| SCHEMBL3294539 | 0.77 | CDK1 (0.46) | HSP90AB1HSP90AA1 | |
| SCHEMBL9177023 | 0.77 | CYP3A4 (0.49) | HSP90AB1HSP90AA1HSP90B1TRAP1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723319-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2010-05-25 | — | — | US | disclosed |
| US-20100004440-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | CHO DONG-GYU | 2010-01-07 | — | — | US | disclosed |
| US-7605147-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2009-10-20 | — | — | US | disclosed |
| US-7157448-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2007-01-02 | — | — | US | disclosed |
| US-7157448-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004440-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | HSP90AB1 3304/4885HSP90AA1 4081/4885HSP90B1 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.